Mr. Joshua Bartch reports

SUSPENSION OF TRADING

Mydecine Innovations Group Inc.'s shares have been suspended from trading on the Aquis Growth Market for failure to pay exchange fees pursuant to Rule 3.10 of the Aquis Stock Exchange Rulebook (Access) with effect from today, Oct. 10, 2024.

The directors of Mydecine take responsibility for this news release.

This news release contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of United Kingdom domestic law, by virtue of the European Union (Withdrawal) Act 2018 (MAR), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

About Mydecine Innovations Group Inc.

Mydecine is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Mydecine's dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Mydecine's approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with world-class scientific and regulatory expertise.